BioHealth News Archive

How Do You Start A Biotech Company?

How Do You Start A Biotech Company?

To launch a company that might attract the investment you need to develop a promising new drug candidate or research tool you need to…

Read More
MedImmune spinout Viela Bio raising another $75M – Washington Business Journal

MedImmune spinout Viela Bio raising another $75M – Washington Business Journal

Viela Bio had raised $282 million when it launched at the end of February 2018. {iframe}https://www.bizjournals.com/washington/news/2019/03/22/medimmune-spinout-raising-another-75m-to-get-first.amp.html{/iframe}

Read More
Takeda and HemoShear Therapeutics Extend Exclusive Drug Discovery Partnership in Liver Diseases

Takeda and HemoShear Therapeutics Extend Exclusive Drug Discovery Partnership in Liver Diseases

HemoShear Therapeutics, LLC, a privately held biotechnology company, today announced an extension of its partnership with Takeda Pharmaceutical Company Limited to discover and develop…

Read More
Paragon Bioservices Appoints New CTSO, Bolsters Leadership Ranks to Support Late-Stage Clinical and Commercial Biopharmaceutical Manufacturing – Paragon Bioservices, Inc.

Paragon Bioservices Appoints New CTSO, Bolsters Leadership Ranks to Support Late-Stage Clinical and Commercial Biopharmaceutical Manufacturing – Paragon Bioservices, Inc.

Paragon Bioservices, the leading private equity-backed, biologics contract development and manufacturing organization (CDMO) announced today the appointment of Thomas VanCott, Ph.D., as Chief Technology and…

Read More
Emergent BioSolutions Initiates Phase 3 Clinical Study to Evaluate AV7909 for Post-Exposure Prophylaxis of Anthrax | Vaccines | News Channels

Emergent BioSolutions Initiates Phase 3 Clinical Study to Evaluate AV7909 for Post-Exposure Prophylaxis of Anthrax | Vaccines | News Channels

Emergent BioSolutions Inc. (NYSE:EBS) today announced the initiation of a Phase 3 trial to evaluate the lot consistency, immunogenicity, and safety of AV7909 (anthrax…

Read More
Flagship Pioneering raises $824M in new fund – MedCity News

Flagship Pioneering raises $824M in new fund – MedCity News

A life sciences-focused venture capital firm has raised more than $800 million for its latest fund. {iframe}https://medcitynews.com/2019/03/flagship-pioneering-raises-824m-in-new-fund/?utm_campaign=MCN%20Daily%20Top%20Stories&utm_source=hs_email&utm_medium=email&utm_content=70996491&_hsenc=p2ANqtz-_DY41Wi4agZwnXpClpK4cbqQ25NHFajpbuwFHJqWI6FOaZT9ioU5F3vzEtr6h5qtDt6JmATgA9z29Qud3_m-GZjRRogQ&_hsmi=70996491{/iframe}

Read More
Interview: Viela Bio Eyes BLA for Lead Asset Only One Year After Launch | BioSpace

Interview: Viela Bio Eyes BLA for Lead Asset Only One Year After Launch | BioSpace

One year after spinning out from AstraZeneca’s MedImmune, Viela Bio is already anticipating filing a Biologics License Application with the U.S. Food and Drug…

Read More
Johns Hopkins spinout Vixiar gets $1.5M for tablet-based cardiac measurement system | MobiHealthNews

Johns Hopkins spinout Vixiar gets $1.5M for tablet-based cardiac measurement system | MobiHealthNews

Vixiar, a Johns Hopkins spinout marketing a tablet-based point of care system for assessing cardiac filling pressure, has raised $1.5 million in Series A…

Read More
GSK pancreatic cancer drug heads to phase 1 combo with Merck’s Keytruda after positive mouse trial | FierceBiotech

GSK pancreatic cancer drug heads to phase 1 combo with Merck’s Keytruda after positive mouse trial | FierceBiotech

GlaxoSmithKline’s experimental drug GSK095 is designed to work in tandem with checkpoint inhibiting medicines in the hopes of empowering the immune system to launch a…

Read More
Emergent BioSolutions launches Phase 3 trial of anthrax vaccine – Homeland Preparedness News

Emergent BioSolutions launches Phase 3 trial of anthrax vaccine – Homeland Preparedness News

Emergent BioSolutions said on Tuesday it will begin a Phase 3 trial of a new anthrax vaccine it is developing. The Phase 3 trial…

Read More
Researchers at Johns Hopkins offer new protocol to potentially cure sickle cell disease

Researchers at Johns Hopkins offer new protocol to potentially cure sickle cell disease

There's new hope for patients who have blood diseases. Johns Hopkins Kimmel Cancer Center researchers say a new protocol offers the possibility of a…

Read More
What’s behind sky-high valuations of biopharma startups? – MedCity News

What’s behind sky-high valuations of biopharma startups? – MedCity News

2018 was undoubtedly one of the most important years ever for biopharma, setting records for valuations and dealmaking. But a paper published in January…

Read More
Altimmune Announces Positive Results from NasoVAX Extension Study

Altimmune Announces Positive Results from NasoVAX Extension Study

Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced additional positive data from a Phase 2 extension study of its NasoVAX intranasal influenza…

Read More
Biopharma breathes ‘sigh of relief’ with HHS’ interim FDA appointment: analyst | FiercePharma

Biopharma breathes ‘sigh of relief’ with HHS’ interim FDA appointment: analyst | FiercePharma

It didn’t take long for the Trump administration to tap Ned Sharpless, now director of the National Cancer Institute, to take the reins at…

Read More
Sonavex readies to launch sales of medical tech with new FDA clearance – Baltimore Business Journal

Sonavex readies to launch sales of medical tech with new FDA clearance – Baltimore Business Journal

Sonavex is first targeting the reconstructive surgery market with its new medical technology, which just earned its final FDA clearance. {iframe}https://www.bizjournals.com/baltimore/news/2019/03/14/sonavex-readies-to-commercially-launch-medical.amp.html?__twitter_impression=true{/iframe}

Read More